Submit an abstract by July 13 and share your work with the global breast cancer research community at #SABCS26 (December 8-11). Learn more: buff.ly/TJKb4se

The abstract deadline for #SABCS26 is July 13. Submit an abstract today and join us December 8-11 for the most important breast cancer meeting in the world. Learn more: buff.ly/TJKb4se

SABCS co-directors Virginia Kaklamani, MD, and Carlos Arteaga, MD, and program director Kate Lathrop, MD, joined colleagues from around the world at #ASCO26 last week. What discoveries will define the next chapter of breast cancer research? Join us at #SABCS26 to find out. @vkaklamani.bsky.social

Breast cancer clinicians and scientists from around the world will come together at #SABCS26 (December 8-11). Submit an abstract by July 13 and join them. Learn more: buff.ly/TJKb4se

The William L. McGuire Award and Lectureship—which honors Dr. McGuire, a co-founder of SABCS—will be presented at #SABCS26 to recognize an investigator who has made enduring contributions to breast cancer research and patient care. Nominate a colleague by May 29: buff.ly/9iRLmv0

Submit an abstract by July 13 and share your work with the global breast cancer research community at #SABCS26 (December 8-11). Learn more: buff.ly/TJKb4se

The William L. McGuire Award and Lectureship is presented annually at SABCS to an investigator whose contributions to translational and clinical research have advanced the understanding of breast cancer pathogenesis and improved patient outcomes. Nominate a colleague by May 29: buff.ly/9iRLmv0

Abstract submission is now open for the San Antonio Breast Cancer Symposium, December 8-11, 2026. Abstract deadline: July 13. Learn more: buff.ly/TJKb4se #SABCS26

Relive the sights and memorable moments from San Antonio in the #SABCS25 Photo Gallery. View now in SABCS Meeting News: buff.ly/zrdns5H

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more: buff.ly/Uc3UCkZ

The final General Session at #SABCS25 featured supportive interventions for survivors, menopausal hormone therapy risk analysis, and more. Learn more in SABCS Meeting News: buff.ly/dkUM48A

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more: buff.ly/Z5orepv

The View from the Trenches session that closed out #SABCS25 provided clinical context for the cutting-edge data presented from across the continuum of breast cancer research. Read a recap in SABCS Meeting News: buff.ly/p5WGxsF

During her award lecture at #SABCS25, @AACR Outstanding Investigator Awardee Sara Tolaney emphasized the importance of always putting patients first. Learn more in SABCS Meeting News: buff.ly/umygAOs

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more: buff.ly/Uc3UCkZ

Partnership in Progress: Panelists at #SABCS25 discussed the vital role of patient advocacy in advancing breast cancer research, policy, and care. Learn more in SABCS Meeting News: buff.ly/8gTmK7p

2025 William L. McGuire Memorial Lecture Award recipient Armando E. Giuliano, MD, reflected on successes and setbacks related to his career-defining studies at #SABCS25. Learn more in SABCS Meeting News: buff.ly/gVgMCBC

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more: buff.ly/Uc3UCkZ

Experts revealed findings from de-escalation trials, preoperative radiotherapy study, and more during the second General Session at #SABCS25. Learn more in SABCS Meeting News: buff.ly/ao6GGJC

The inaugural SABCS Salutes Patients and Survivors event at #SABCS25 emphasized the importance of empowering this vital community. Learn more in SABCS Meeting News: buff.ly/qxJSLN9

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more: buff.ly/Z5orepv

Experts reported potentially practice-changing findings, including data from lidERA and HER2CLIMB-05 trials, during the first General Session at #SABCS25. Learn more in SABCS Meeting News buff.ly/dkUM48A

#SABCS25 recap: Joan Brugge, PhD, shared new insights into breast tumorigenesis in BRCA1/2-mutation carriers. Learn more in SABCS Meeting News: buff.ly/8BJVpIA

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more: buff.ly/Uc3UCkZ

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more: buff.ly/Z5orepv

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more: buff.ly/Z5orepv

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more: buff.ly/Z5orepv

#SABCS25 recap: Panelists examined the latest knowledge about the connections between breast cancer and lifestyle factors. Learn more in SABCS Meeting News: buff.ly/zFi38MB

#SABCSSnippets: Marcela Mazo talked with Marjolein Smidt at #SABCS25 about the results of the Phase III BOOG 2013-08 trial, which indicate that sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer. buff.ly/MrXAKvF

#SABCSSnippets: Saba Shaikh talked with Sonia Pernas at #SABCS25 about the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib + fulvestrant showed efficacy in HR+ metastatic breast cancer patients previously treated with a CDK4/6 inhibitor. buff.ly/gkjdRPf

Ruth O'Regan summarizes the 2025 FDA approvals for HR+ metastatic breast cancer, including datopotamab deruxtecan, trastuzumab deruxtecan, and imlunestrant. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH

#SABCSSnippets: Rahul Gosain of the Oncology Brothers talked with Marleen Kok at #SABCS25 about how lobular carcinoma—which comprises 10-15% of all invasive breast cancers—differs from ductal carcinoma. buff.ly/r4mA3Vx @marleenkok.bsky.social @oncbrothers.bsky.social

Hope Rugo reviews biomarker subgroup results from the evERA phase III trial, updated EMBER-3 efficacy of imlunestrant in advanced breast cancer, and WISDOM 1.0 findings on risk-based screening. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH @hoperugo.bsky.social

Hope Rugo shares the first positive results for an oral SERD (giredestrant) in the adjuvant setting and key findings from the phase III lidERA trial in ER+, HER2− early breast cancer. Watch now in the Best of #SABCS25: https//buff.ly/fUHtwnq @hoperugo.bsky.social

#SABCSSnippets at #SABCS25: Julie Nangia and @ErikaHamilton9 discussed HER2CLIMB-05, which showed that adding tucatinib to 1st-line maintenance therapy with trastuzumab and pertuzumab delayed progression in patients with HER2+ metastatic breast cancer. buff.ly/YIwYQEh @erikahamilton9.bsky.social

Janice Tsang reviews a year in metastatic breast cancer, highlighting key trial updates in TNBC, HER2+ and HR+/HER2− disease—including ASCENT, DESTINY-Breast, HER2CLIMB, EMBER-3 and SERENA-6. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH

William Gradishar reviews key #SABCS25 findings in early breast cancer, including neoadjuvant trials TBCRC056 and OlympiA exploring PARP inhibitors and immunotherapy in BRCA-mutated disease. Watch now in the Best of SABCS®: buff.ly/vDfAHmH

#SABCSSnippets: Virginia Kaklamani talked with Hope Rugo at #SABCS25 about the field of endocrine therapy, including data from the Phase III evERA Breast Cancer Study and from the Phase II ELEVATE Study. buff.ly/Bw3mSWW @vkaklamani.bsky.social @hoperugo.bsky.social

#SABCSSnippets: Virginia Kaklamani talked with Laura Esserman about the results of the WISDOM 1.0 study, which demonstrated that risk-based breast cancer screening is safe, preferred by women, and identifies the highest risk individuals. buff.ly/DFByGvB @vkaklamani.bsky.social

Close out #SABCS25 with the Year in Review and View from the Trenches sessions on Friday afternoon. More details in SABCS Meeting News: buff.ly/NMwi7Nk

Experts will explore whether all patients with early-stage breast cancer need axillary staging during an #SABCS25 debate on Friday afternoon. Learn more: buff.ly/dsX3CkF

Sara M. Tolaney, MD, MPH, AACR Outstanding Investigator Award for Breast Cancer Research recipient, will present an award lecture on Friday afternoon at #SABCS25. Read more: buff.ly/Dnsf4Rd

Friday's Poster Spotlight Sessions at #SABCS25 covered a wide range of topics, including the application of AI to pathology and risk stratification, locoregional challenges, and CNS metastases.

#SABCS25 Patient Advocacy Spotlight: Marcela Mazo Canola, MD, and Laurel Pointer reflect on their relationship as physician and patient. Read now in SABCS Meeting News: buff.ly/84wgwzX

Real Impact with Artificial Intelligence: Johan Hartman, Tufia Haddad, Amrita Basu, and advocate Carole L Baas explored this topic in an #SABCS25 educational session moderated by Frederick M Howard.

Elie Rassy, Gustavo Werutsky, Sara Tolaney, and advocate Janice Cowden discussed "How to Treat TNBC" in an #SABCS25 educational session moderated by Marleen Kok.

Patients are at the heart of the SABCS mission. We thank our patient advocate attendees for their enthusiastic participation in the Symposium and for their critical contributions to the #SABCS25 program.

Targeting the Non-T Cell Microenvironment: Fatima Mechta-Grigoriou, Kelly Kersten, George Plitas, and advocate Cheryl Jernigan addressed this topic in an #SABCS25 State of the Art session moderated by Christos Sotiriou.

Management of the Axilla in Multidisciplinary Care: Giacomo Montagna, Lori Pierce, Sherry Shen, and advocate N. Beth Emery addressed this topic in an #SABCS25 Clinical Controversies session moderated by Tari A. King. @sherryshenmd.bsky.social

Patient advocate Marissa Thomas, CEO of The Breast of Us, will speak during a Friday afternoon session at #SABCS25 on body image, hair loss, and skin health after cancer treatment. Learn more in SABCS Meeting News: buff.ly/kVLAcSv